eligibility_summary
Eligible: unresectable/metastatic left-sided colorectal adenocarcinoma, KRAS/NRAS/BRAF wild-type, measurable disease (RECIST 1.1), ECOG 0–1, agree to provide fresh tumor tissue. Exclude: history/current/suspected ILD/pneumonitis/fibrosis, allergies to amivantamab/cetuximab or mFOLFOX6/FOLFIRI components, interfering second malignancy, dMMR/MSI‑H with HER2+ tumor, prior EGFR or MET‑targeted therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 first-line left‑sided mCRC (KRAS/NRAS/BRAF WT). Interventions: Amivantamab (bispecific IgG1 monoclonal antibody to EGFR and MET, blocks ligand binding/signaling, promotes receptor internalization/degradation, and mediates Fc‑dependent ADCC) plus chemotherapy (mFOLFOX6 or FOLFIRI) versus Cetuximab (anti‑EGFR IgG1 monoclonal antibody, signal blockade and ADCC) plus the same chemotherapy. Chemo mechanisms: 5‑fluorouracil (antimetabolite, thymidylate synthase inhibition), leucovorin (potentiates 5‑FU), oxaliplatin (platinum DNA crosslinker), irinotecan (topoisomerase I inhibitor). Targets: EGFR and MET on colorectal tumor cells, downstream RAS‑RAF‑MEK‑ERK and PI3K‑AKT pathways, MET/HGF signaling, and tumor DNA replication/synthesis, with immune effector engagement via ADCC.